Q3 EPS Forecast for Oruka Therapeutics Boosted by Analyst

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities research analysts at HC Wainwright raised their Q3 2025 earnings estimates for shares of Oruka Therapeutics in a research report issued on Monday, October 27th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.50) per share for the quarter, up from their prior forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.43) EPS.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02.

A number of other research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 8th. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 12th. BTIG Research reaffirmed a “buy” rating and issued a $56.00 price target on shares of Oruka Therapeutics in a research note on Monday, September 29th. Finally, Barclays started coverage on shares of Oruka Therapeutics in a research report on Monday, October 13th. They set an “overweight” rating and a $48.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Oruka Therapeutics Stock Up 0.6%

Shares of NASDAQ:ORKA opened at $27.61 on Wednesday. The company’s 50 day moving average price is $19.62 and its two-hundred day moving average price is $14.73. Oruka Therapeutics has a 12-month low of $5.49 and a 12-month high of $30.40. The firm has a market cap of $1.15 billion, a PE ratio of -9.83 and a beta of -0.29.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in Oruka Therapeutics during the second quarter worth $28,000. Ameritas Investment Partners Inc. bought a new position in Oruka Therapeutics during the second quarter worth $31,000. BNP Paribas Financial Markets raised its stake in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in Oruka Therapeutics during the second quarter worth $68,000. Finally, New York State Common Retirement Fund bought a new position in Oruka Therapeutics during the second quarter worth $96,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.